Neurocrine Biosciences Inc (NBIX):企業の財務・戦略的SWOT分析

◆英語タイトル:Neurocrine Biosciences Inc (NBIX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH18235FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年2月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥35,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥52,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Neurocrine Biosciences Inc (NBIX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Neurocrine Biosciences Inc (Neurocrine) discovers, develops and commercializes pharmaceutical products for the treatment of neurologic, psychiatric and endocrine related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule is a US FDA approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD). Its other major pipeline products include elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis and uterine fibroids and opicapone, a catechol-O-methyltransferase inhibitor (COMT inhibitor) intended for adult patients with Parkinson’s disease. It also develops drug candidates for the treatment of essential tremor and classic congenital adrenal hyperplasia. Neurocrine is headquartered in San Diego, California, the US.

Neurocrine Biosciences Inc Key Recent Developments

Feb 04,2021: Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
Jan 08,2021: Neurocrine Biosciences provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones
Nov 09,2020: Neurocrine Biosciences reports third quarter 2020 financial results
Oct 07,2020: Neurocrine Biosciences and Me2/Orchestra, in partnership with mental health advocacy groups, honor Mental Illness Awareness Week by launching monumental moments , an online community platform and charitable initiative
Aug 03,2020: Neurocrine Biosciences reports second quarter 2020 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Neurocrine Biosciences Inc – Key Facts
Neurocrine Biosciences Inc – Key Employees
Neurocrine Biosciences Inc – Key Employee Biographies
Neurocrine Biosciences Inc – Major Products and Services
Neurocrine Biosciences Inc – History
Neurocrine Biosciences Inc – Company Statement
Neurocrine Biosciences Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Neurocrine Biosciences Inc – Business Description
Neurocrine Biosciences Inc – Corporate Strategy
Neurocrine Biosciences Inc – SWOT Analysis
SWOT Analysis – Overview
Neurocrine Biosciences Inc – Strengths
Neurocrine Biosciences Inc – Weaknesses
Neurocrine Biosciences Inc – Opportunities
Neurocrine Biosciences Inc – Threats
Neurocrine Biosciences Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Neurocrine Biosciences Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 04, 2021: Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
Jan 08, 2021: Neurocrine Biosciences provides preliminary fourth quarter and full-year 2020 net product sales results and 2021 program milestones
Nov 09, 2020: Neurocrine Biosciences reports third quarter 2020 financial results
Oct 07, 2020: Neurocrine Biosciences and Me2/Orchestra, in partnership with mental health advocacy groups, honor Mental Illness Awareness Week by launching monumental moments , an online community platform and charitable initiative
Aug 03, 2020: Neurocrine Biosciences reports second quarter 2020 financial results
Jun 17, 2020: Takeda licences psychiatry programmes to Neurocrine Biosciences
May 06, 2020: Neurocrine Biosciences reports first quarter 2020 financial results
Apr 03, 2020: Neurocrine Biosciences provides COVID-19 business update
Feb 04, 2020: Neurocrine Biosciences reports fourth quarter and full-year 2019 financial results
Feb 03, 2020: Neurocrine Biosciences announces appointment of Shalini Sharp to Board of Directors
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Neurocrine Biosciences Inc, Key Facts
Neurocrine Biosciences Inc, Key Employees
Neurocrine Biosciences Inc, Key Employee Biographies
Neurocrine Biosciences Inc, Major Products and Services
Neurocrine Biosciences Inc, History
Neurocrine Biosciences Inc, Subsidiaries
Neurocrine Biosciences Inc, Key Competitors
Neurocrine Biosciences Inc, Ratios based on current share price
Neurocrine Biosciences Inc, Annual Ratios
Neurocrine Biosciences Inc, Annual Ratios (Cont...1)
Neurocrine Biosciences Inc, Annual Ratios (Cont...2)
Neurocrine Biosciences Inc, Interim Ratios
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Neurocrine Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Neurocrine Biosciences Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Neurocrine Biosciences Inc (NBIX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BelAZ:企業の戦略・SWOT・財務分析
    BelAZ - Strategy, SWOT and Corporate Finance Report Summary BelAZ - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • Amathus Public Ltd:企業の戦略・SWOT・財務情報
    Amathus Public Ltd - Strategy, SWOT and Corporate Finance Report Summary Amathus Public Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Northern Ireland Electricity Networks Ltd:企業の戦略的SWOT分析
    Northern Ireland Electricity Networks Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Philippine Long Distance Telephone Co (TEL):企業の戦略的SWOT分析
    Philippine Long Distance Telephone Co (TEL) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Corium International Inc (CORI):医療機器:M&Aディール及び事業提携情報
    Summary Corium International Inc (Corium) is a commercial-stage biopharmaceutical company that produces and develops central nervous system pharmaceutical products. The company develops transdermal healthcare products with the help of Corplex technology platform using small molecules. Its products i …
  • Willis Lease Finance Corp (WLFC):企業の財務・戦略的SWOT分析
    Willis Lease Finance Corp (WLFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Manz AG (M5Z):企業の財務・戦略的SWOT分析
    Manz AG (M5Z) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Landmark Graphics Corp:企業の戦略的SWOT分析
    Landmark Graphics Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Armetheon Inc-製薬・医療分野:企業M&A・提携分析
    Summary Armetheon Inc (Armetheon) is a drug development company that develops novel small molecule drugs for treatment of cardiovascular diseases with high unmet medical need. The company develops anticoagulants and antibiotics that make use of the antibiotic resistance mechanisms to provide bacteri …
  • Harvard University:企業のM&A・事業提携・投資動向
    Harvard University - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Harvard University Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • bet-at-home.com AG (ACX):企業の財務・戦略的SWOT分析
    bet-at-home.com AG (ACX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Global Geophysical Services Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Global Geophysical Services Inc (Global Geophysical) is an oil and gas company that offers geophysical technology solutions. The company offers consulting; reservoir grade 3D data sets and land and marine seismic acquisition; seismic data processing; geophysical, geological and engineering s …
  • Balfour Beatty plc:企業の戦略・SWOT・財務情報
    Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report Summary Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • BSH Hausgerate GmbH:企業の戦略・SWOT・財務情報
    BSH Hausgerate GmbH - Strategy, SWOT and Corporate Finance Report Summary BSH Hausgerate GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Caleres Inc (CAL):企業の財務・戦略的SWOT分析
    Caleres Inc (CAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Virgin Active Limited:企業の戦略・SWOT・財務分析
    Virgin Active Limited - Strategy, SWOT and Corporate Finance Report Summary Virgin Active Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Barra Resources Limited:企業の戦略・SWOT・財務分析
    Barra Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Barra Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • B. Braun Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary B. Braun Medical Inc (B. Braun), a subsidiary of B. Braun Melsungen AG, is a medical device company that provides infusion therapy and pain management technology, products and services. The company’s product portfolio includes TPN compounding bags, parenteral nutrition additives, closed syst …
  • Harvard Bioscience Inc (HBIO):企業の財務・戦略的SWOT分析
    Harvard Bioscience Inc (HBIO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Toleranzia AB-製薬・医療分野:企業M&A・提携分析
    Summary Toleranzia AB (Toleranzia) is a developer of platform technology for the treatment of autoimmune diseases. The company develops and offers products and technologies including Re-Tolerogen for the treatment of autoimmune diseases. Its Re-Tolerogen platform technology is a fusion protein for t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆